Alpha Score of 51 reflects moderate overall profile with poor momentum, strong value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| D.E. Shaw David Shaw | 26.43M | $455.96M | NEW |
| Citadel Ken Griffin | 7.70M | $132.84M | NEW |
| Marshall Wace | 5.83M | $100.51M | NEW |
| Soros Fund Management George Soros (founder) | 1.25M | $21.50M | NEW |
| Point72 Steve Cohen | 942K | $16.25M | NEW |
| Greenlight Capital David Einhorn | 554K | $11.94M | NEW |
Kenvue Inc. is the world's largest pure-play consumer health company, specializing in science-backed products for everyday care needs. It operates through three key segments: Self Care, offering cough, cold, allergy, pain, digestive health, smoking cessation, and eye care under brands like Tylenol, Motrin, Benadryl, Nicorette, and Zyrtec; Skin Health and Beauty, providing face, body, hair, sun, and other care items via Neutrogena, Aveeno, Rogaine, and OGX; and Essential Health, delivering oral, baby, women's health, wound care, and related products through Listerine, Johnson's, Band-Aid, and Stayfree. Kenvue serves consumers in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America, focusing on trusted, iconic brands that support daily rituals and critical moments with innovation rooted in clinical research and consumer insights. Incorporated in 2022 and headquartered in Summit, New Jersey, Kenvue emphasizes integrity, quality, and solutions endorsed by healthcare professionals across diverse categories like pain relief, skin care, and oral health.
Earnings calendar coming soon. Subscribe to get notified when KVUE reports next.
Get earnings alerts →